Drug
Peginterferon alfa-2a clinical trials
Also written Pegasys and Pegylated interferon alfa-2a.
- studies test it
- 237
- open now
- 3
- in phase 3
- 64
- first study started
- 2000
Keep track of what changes. Save the peginterferon alfa-2a studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Pegasys
- 90
Other names
Studies by the year they started
236 studies that test it; most in 2012 (23)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2001 | 3 |
| 2002 | 6 |
| 2003 | 15 |
| 2004 | 18 |
| 2005 | 22 |
| 2006 | 18 |
| 2007 | 21 |
| 2008 | 9 |
| 2009 | 16 |
| 2010 | 10 |
| 2011 | 22 |
| 2012 | 23 |
| 2013 | 7 |
| 2014 | 3 |
| 2015 | 14 |
| 2016 | 11 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 22
- Phase 2
- 62
- Phase 3
- 64
- Phase 4
- 88
- No phase
- 13
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 114 · Other 123
Hoffmann-La Roche (61) · Vertex Pharmaceuticals Incorporated (11) · National Taiwan University Hospital (9) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (8) · Bristol-Myers Squibb (8) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Kaohsiung Medical University Chung-Ho Memorial Hospital (6) · Beijing Ditan Hospital (5)
Often tested with
Tested in the same studies.
Ribavirin (100) · Telaprevir (15) · Daclatasvir (8) · Tenofovir (5) · Ritonavir (4) · Interferon alpha-2 (4) · Entecavir (4) · Simeprevir (3)
Studies
Open first, then newest update. How each study uses peginterferon alfa-2a is read from its arms, and is right about nine times in ten.
Testing it · 237
- AlloHCT With PegINFa for MyelofibrosisRecruitingPhase 1University of UtahNCT05535764Written as Pegylated interferon alpha2a
- A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis BRecruitingPhase 1IntegerBioNCT07389044Written as Peginterferon Alfa-2A
- Effect of Low-dose Interferon-alfa2a on Peri-operative Immune SuppressionRecruitingPhase 2Zealand University HospitalNCT04798612Written as Pegasys
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis BActive, not recruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT06092333Written as VIR-2218 and peginterferon alfa-2a
- Interferon Alfa Therapy Based on Th17 Profile in Membranous NephropathyTerminatedPhase 2Centre Hospitalier Universitaire de NiceNCT05941845Written as Peginterferon Alfa-2A 180 MCG/ML Injectable Solution
- Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected PatientsCompletedPhase 2University Hospital, BordeauxNCT00221650Written as Peginterferon alfa2a
- Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionCompletedPhase 2Vir Biotechnology, Inc.NCT04412863Written as pegylated interferon-alfa 2a
- Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous AngiosarcomaWithdrawnPhase 1M.D. Anderson Cancer CenterNCT05799612Written as PEGYLATED-INTERFERON ALPHA-2A
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis CCompletedPhase 3Tanabe Pharma CorporationNCT01753557Written as PEG-IFN alfa-2a
- HBsAg Loss Adding Pegylated Interferon in HBeAg-negative PatientsCompletedNot applicableJosé Antonio CarrionNCT02743182Written as Pegylated interferon alfa-2a
- Peg-interferon for Inactive Chronic Hepatitis B CarriersCompletedPhase 2/3Seng Gee LimNCT02992704Written as Peginterferon Alfa-2A
- Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General HospitalCompletedPhase 4Nanogen Pharmaceutical Biotechnology Joint Stock CompanyNCT06922643Written as Peginterferon Alfa-2A
- SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).CompletedPhase 2Hoffmann-La RocheNCT00442572Written as PEGASYS [peginterferon alfa-2a]
- Switching Regimen in Treating Cirrhotic HCV GT1b SubjectsCompletedPhase 2Humanity and Health Research CentreNCT02583685Written as PR4 + LDV/SOF + ASV 4 wk
- Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)CompletedPhase 2Gilead SciencesNCT03852433Written as Peginterferon Alfa-2a (PEG-IFN alfa)
- Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral TherapyCompletedPhase 1/2Massachusetts General HospitalNCT02471430Written as Pegylated Interferon-alpha2a
- Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/RelapsersTerminatedEarly Phase 1University of NebraskaNCT00882193Written as Peginterferon alpha 2a
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionCompletedPhase 4Tanta UniversityNCT02992457Written as Pegylated-interferon alfa-2a
- Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive PatientsWithdrawnNot applicableUniversity of NebraskaNCT00571714Written as Peginterferon alpha-2a and ribavirin
- Cemiplimab/Peg-Interferon-α in Advanced CSCCWithdrawnPhase 1Baptist Health South FloridaNCT05729139Written as PEG-IFN alfa-2a
See all 237 studies that test peginterferon alfa-2a →
Given in every arm · 113 — peginterferon alfa-2a is usual care beside what is tested
- DOC1021 Dendritic Cell Immunotherapy for Refractory MelanomaRecruitingPhase 1/2Diakonos Oncology CorporationNCT07288112Written as pIFN (peginterferon alfa-2a)
- Lonafarnib With and Without Ritonavir in HDV (LOWR-1)CompletedPhase 2EIT Pharma, Inc.NCT02430181Written as peginterferon alfa-2a
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B InfectionCompletedPhase 2Arbutus Biopharma CorporationNCT04980482Written as Peg-IFNα-2a
- Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin RegimenCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT01332955Written as pegIFN alfa-2a
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)TerminatedPhase 2Arrowhead PharmaceuticalsNCT02577029Written as pegylated interferon alpha 2a
- HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /RibavirinTerminatedPhase 3Anna CrucetaNCT01718301Written as Peginterferon alfa-2a
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04439539Written as PegIFN-alpha-2a
- A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04585789Written as PegIFN-alpha-2a (Optional)
- A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy ParticipantsTerminatedPhase 1Bristol-Myers SquibbNCT06144697Written as Pegasys
- A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04667104Written as PegIFN-alpha2a
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus InfectionTerminatedPhase 2Janssen Research & Development, LLCNCT05005507Written as PegIFN-alpha-2a
- Telaprevir in Genotype 3 HCVCompletedPhase 4Queen Mary University of LondonNCT02087111Written as 40 Kd Pegylated interferon alfa 2a
- A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With EntecavirCompletedPhase 2Enyo PharmaNCT04365933Written as Pegylated interferon alpha2a
- High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCVCompletedPhase 3Foundation for Liver ResearchNCT00381953Written as Peginterferon alfa-2a
- A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT02174172Written as PEG-interferon alfa-2a
- REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B InfectionCompletedPhase 2Replicor Inc.NCT02565719Written as Pegasys
- Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver FibrosisStatus unknownNot applicableThird Affiliated Hospital, Sun Yat-Sen UniversityNCT03920605Written as Peginterferon Alfa-2a
- A Study in Healthy Volunteers and Patients With Chronic Hepatitis BCompletedPhase 1Assembly BiosciencesNCT02908191Written as Pegasys
- Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)CompletedPhase 3R-PharmNCT03833362Written as Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b
- A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.CompletedPhase 3Hoffmann-La RocheNCT01088659Written as peginterferon alfa-2a [Pegasys]
Showing 20 of 113.
As the comparator · 28 — what is tested is compared with peginterferon alfa-2a
- A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis CCompletedPhase 1/2HanAll BioPharma Co., Ltd.NCT01194037Written as Peginterferon alfa-2a
- Single Dose Escalation Study of P1101 in Healthy Adult Male SubjectsCompletedPhase 1PharmaEssentiaNCT05129644Written as Pegasys
- Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 InfectionCompletedPhase 2PharmaEssentiaNCT01587586Written as PEGASYS 180 µg Q1W
- Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B PatientCompletedPhase 1/2Tianjin SinoBiotech Ltd.NCT03294798Written as Pegasys
- A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)TerminatedPhase 3Merck Sharp & Dohme LLCNCT01641926Written as PEGASYS™
- An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis CCompletedPhase 3BiocadNCT01889433Written as Pegasys
- A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment BeforeCompletedPhase 3AbbVieNCT01854697Written as Pegylated Interferon alpha 2-a (PegIFN)
- Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)CompletedPhase 3Merck Sharp & Dohme LLCNCT00081770Written as PEGASYS (peginterferon alfa-2a)
- A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHBStatus unknownPhase 1/2Third Affiliated Hospital, Sun Yat-Sen UniversityNCT02615639Written as IFN-a-2a
- Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e AntigenCompletedPhase 2Bristol-Myers SquibbNCT01204762Written as pegIFNα-2a
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedPhase 2Bristol-Myers SquibbNCT01309932Written as Pegylated Interferon Alfa-2a (pegIFNα-2a)
- Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis CCompletedPhase 3Beijing Kawin Technology Share-Holding Co., Ltd.NCT01903278Written as Pegasys /RBV
- Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis BCompletedPhase 3Xiamen Amoytop Biotech Co., Ltd.NCT01760122Written as Pegasys
- Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis CCompletedPhase 3Bristol-Myers SquibbNCT01754974Written as Peginterferon alfa-2a
- Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B PatientsCompletedPhase 1/2Beijing Bio-Fortune Ltd.NCT01997944Written as Pegasys
- A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis CCompletedPhase 2Beijing Kawin Technology Share-Holding Co., Ltd.NCT01908335Written as Pegasys /RBV
- Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C PatientsCompletedPhase 3Xiamen Amoytop Biotech Co., Ltd.NCT01581398Written as Pegasys
- Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult SubjectsCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT01504581Written as Pegasys
- Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)Status unknownPhase 1/2Hanmi Pharmaceutical Company LimitedNCT02057887Written as Pegasys
- Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3CompletedPhase 3Human Genome Sciences Inc.NCT00411385Written as peginterferon alfa-2a
Showing 20 of 28.
Codes
What other systems call peginterferon alfa-2a · ClinicalTrials.gg INT003922
- MeSH (NLM) C100416peginterferon alfa-2aConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) Q46947FE7KPEGINTERFERON ALFA-2AConfirmed FDA, NLM, Wikidata
- RxNorm 120608Confirmed FDA, Wikidata
- Wikidata Q420056peginterferon alfa-2aConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C33987Peginterferon Alfa-2aOne source FDA
- DrugBank DB00008One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C100416 | peginterferon alfa-2a | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | Q46947FE7K | PEGINTERFERON ALFA-2A | Confirmed FDA, NLM, Wikidata |
| RxNorm | 120608 | — | Confirmed FDA, Wikidata |
| Wikidata | Q420056 | peginterferon alfa-2a | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C33987 | Peginterferon Alfa-2a | One source FDA |
| DrugBank | DB00008 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.